Obexelimab: A New Hope for IgG4-RD Treatment?
Exciting results from an open-label Phase 2 pilot trial published in Lancet Rheumatology[1] suggest that obexelimab, a potential new treatment for IgG4-related disease (IgG4-RD), may become an ...
In Conversation With... John H. Stone, MD MPH
“Steroids have a role in treating so many diseases - and yet, they do not cure any of them.” John H. Stone, MD MPH is a Professor of Medicine at Harvard Medical School, and the Edward A. Fox Chair in ...
TitAIN Trial Provides Hope to Giant Cell Arteritis Patients
A recent phase 2 safety and efficacy study of an anti-interleukin-17A monoclonal antibody for the treatment of giant cell arteritis patients suggests there may soon be another alternative to ...
Steroid-toxicity should, and can now be, measured in routine clinical practice
Glucocorticoids have saved countless lives since being discovered 75 years ago. Yet, long-term exposure is associated with a range of toxicities including an increased risk of devastating adverse ...
In Conversation With… Wen Zhang, MD PhD
“We have a saying in China, ‘to turn pale at the mention of a tiger’, and this describes the fear many patients show when told they need to be prescribed steroids.” Wen Zhang, MD PhD is a Professor ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
